Kala Pharmaceuticals Stock Today
| KALA Stock | USD 6.80 0.23 3.27% |
PerformanceModest
| Odds Of DistressHigh
|
Kala Pharmaceuticals is trading at 6.80 as of the 21st of March 2025, a 3.27 percent decrease since the beginning of the trading day. The stock's open price was 7.03. Kala Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2017 | Category Healthcare | Classification Health Care |
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. Kala Pharmaceuticals, Inc. The company has 6.09 M outstanding shares of which 300.69 K shares are now shorted by private and institutional investors with about 3.1 trading days to cover. More on Kala Pharmaceuticals
Moving against Kala Stock
Kala Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Mark Iwicki | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKala Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kala Pharmaceuticals' financial leverage. It provides some insight into what part of Kala Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kala Pharmaceuticals (KALA) is traded on NASDAQ Exchange in USA. It is located in 1167 Massachusetts Avenue, Arlington, MA, United States, 02476 and employs 43 people. Kala Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.82 M. Kala Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 6.09 M outstanding shares of which 300.69 K shares are now shorted by private and institutional investors with about 3.1 trading days to cover.
Kala Pharmaceuticals currently holds about 44.57 M in cash with (27.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kala Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Kala Pharmaceuticals is $42.82 Million. Over half of Kala Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Kala Ownership Details
Kala Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Board Of Ttees Leland Stanford Jr Univ | 2024-12-31 | 21.1 K | |
| Two Sigma Investments Llc | 2024-12-31 | 11.9 K | |
| Citigroup Inc | 2024-12-31 | 5.7 K | |
| Ubs Group Ag | 2024-12-31 | 3.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 972 | |
| Covestor Ltd | 2024-12-31 | 969 | |
| Tower Research Capital Llc | 2024-12-31 | 712 | |
| Compagnie Lombard, Odier Sca | 2024-12-31 | 400 | |
| Mccormack Advisors International | 2024-12-31 | 300 | |
| Baker Bros Advisors Lp | 2024-12-31 | 1.2 M | |
| Cormorant Asset Management, Llc | 2024-12-31 | 603 K |
Kala Pharmaceuticals Historical Income Statement
Kala Stock Against Markets
Kala Pharmaceuticals Corporate Management
| CPA CPA | CFO Treasurer | Profile | |
| Patrick Bedell | Executive Channels | Profile | |
| Jill Steier | Executive Communications | Profile | |
| Carl Rennie | Executive Management | Profile | |
| MBA JD | Chief Officer | Profile | |
| Todd Bazemore | Interim Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.